Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -217.90K | -246.60K | -866.30K | -181.10K | -341.70K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.00K | 9.80K | 518.30K | 12.40K | 13.20K |
| Change in Net Operating Assets | -112.30K | 108.30K | 107.70K | -205.10K | 309.90K |
| Cash from Operations | -320.20K | -128.60K | -240.30K | -373.80K | -18.60K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 93.80K | 925.00K | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 75.00K | 683.10K | 0.00 | 0.00 | 2.60K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -23.80K | -64.20K | -- |
| Cash from Financing | 55.30K | 492.30K | 50.90K | 605.60K | 1.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -264.90K | 363.70K | -189.40K | 231.80K | -16.70K |